Guselkumab Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the QUASAR Phase 3 Induction Study

被引：0

作者：

Bressler, Brian ^{[1
]}

Feagan, Brian G. ^{[2
]}

Panes, Julian ^{[3
]}

Lichtenstein, Gary R. ^{[4
]}

Huang, Kuan-Hsiang G. ^{[5
]}

Germinaro, Matthew ^{[5
]}

Pandya, Dwiti ^{[5
]}

Han, Chenglong ^{[6
]}

Miao, Ye ^{[5
]}

Zhang, Hongyan ^{[5
]}

Lateef, Syed ^{[7
]}

Petroniene, Rima ^{[8
]}

Rayyan, Yaser ^{[9
]}

Peyrin-Biroulet, Laurent ^{[10
,11
]}

Rubin, David T. ^{[12
]}

Hisamatsu, Tadakazu ^{[13
]}

机构：

[1] St Pauls Hosp, Vancouver, BC, Canada

[2] Western Univ, London, ON, Canada

[3] Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Catalonia, Spain

[4] Univ Penn, Philadelphia, PA USA

[5] Janssen Res & Dev LLC, Spring House, PA USA

[6] Janssen Global Serv LLC, Malvern, PA USA

[7] Gastro Hlth, Kissimmee, FL USA

[8] Barrie GI Associates, Barrie, ON, Canada

[9] Univ Jordan, Amman, Jordan

[10] Lorraine Univ, CHU Nancy, Vandoeuvre Les Nancy, Lorraine, France

[11] Lorraine Univ, Last Inserm U954, Vandoeuvre Les Nancy, Lorraine, France

[12] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA

[13] Kyorin Univ, Sch Med, Tokyo, Tokyo, Japan

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S1060

引用

页码：S807 / S808

页数：2

共 50 条

[31] Guselkumab improves health-related quality of life as measured by PROMIS-29 in participants with moderately to severely active Crohn's disease: Phase 3 GRAVITI study
Sands, B.
Danese, S.
Cao, Q.
Steinwurz, F.
Kierkus, J.
Han, C.
Olurinde, M.
Yang, Z.
Merrall, E.
Terry, N. A.
Hart, A.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2102 - i2104
[32] The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History
Allegretti, Jessica R.
Panes, Julian
Peyrin-Biroulet, Laurent
Sands, Bruce E.
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Zhan, Jia
Zhang, Hongyan
Begun, Jakob
Kierkus, Jaroslaw
Kravchenko, Tetiana
Hisamatsu, Tadakazu
Rubin, David T.
Bressler, Brian
Dignass, Axel
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S882 - S882
[33] Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance
Panes, J.
Loftus, E. V. J.
Higgins, P.
Lindsay, J. O.
Zhou, W.
Yao, X.
Ilo, D.
Phillips, C.
Tran, J.
Sanchez Gonzalez, Y.
Vermeire, S.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I373 - I374
[34] Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance
Panes, J.
Loftus, E. V. J.
Higgins, P.
Lindsay, O.
Zhou, W.
Yao, X.
Ilo, D.
Phillips, C.
Tran, J.
Gonzalez, Y. Sanchez
Vermeire, S.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I373 - I374
[35] Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study
Panes, Julian
Dignass, Axel
Hisamatsu, Tadakazu
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Sridhar, Sunandini
Branigan, Patrick
Wilson, Rebbecca
Zhang, Hongyan
Magro, Fernando
Jairath, Vipul
Feagan, Brian G.
Lichtenstein, Gary R.
Rubin, David T.
Sands, Bruce E.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1041 - S1041
[36] The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced
Rubin, David T.
Allegretti, Jessica R.
Sands, Bruce E.
Huang, Kuan-Hsiang
Kavalam, Mary
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Mihaly, Emese
Hisamatsu, Tadakazu
Dignass, Axel
Panes, Julian
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S500 - S501
[37] Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
Sands, Bruce E.
Feagan, Brian G.
Gibble, Theresa Hunter
Traxler, Kristina A.
Morris, Nathan
Eastman, William J.
Schreiber, Stefan
Jairath, Vipul
Long, Millie D.
Armuzzi, Alessandro
CROHNS & COLITIS 360, 2023, 5 (04)
[38] Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn's disease: Results from induction and maintenance phase 3 trials
Ghosh, S.
Feagan, B.
Parra, R. S.
Lopes, S.
Steinlauf, A.
Kakuta, Y.
Joshi, N.
Lee, W. J.
Remple, V.
Lacerda, A. P.
Zhou, Q.
Xuan, S.
Louis, E.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 560 - +
[39] UPADACITINIB IMPROVED FATIGUE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM INDUCTION AND MAINTENANCE PHASE 3 TRIALS
Ghosh, Subrata
Feagan, Brian G.
Parra, Rogerio S.
Lopes, Susana
Steinlauf, Adam F.
Kakuta, Yoichi
Joshi, Namita
Lee, Wan-Ju
Remple, Valencia
Lacerda, Ana P.
Zhou, Qian
Xuan, Si
Louis, Edouard
GASTROENTEROLOGY, 2023, 164 (06) : S1106 - S1106
[40] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Watanabe, Mamoru
Motoya, Satoshi
Watanabe, Kenji
Ogata, Haruhiko
Kanai, Takanori
Matsui, Toshiyuki
Suzuki, Yasuo
Shikamura, Mitsuhiro
Igeta, Masataka
Oda, Kazunori
Hori, Tetsuharu
Araki, Takahiro
Hibi, Toshifumi
GASTROENTEROLOGY, 2018, 154 (06) : S380 - S381

← 1 2 3 4 5 →